Noveris Health Sciences Inc.
NVRS
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -78.27% | -78.86% | -67.67% | -55.92% | -58.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.48% | -80.94% | -121.07% | -95.67% | -63.86% |
| Operating Income | 80.48% | 80.94% | 121.07% | 95.67% | 63.86% |
| Income Before Tax | 162.66% | 188.43% | 117.73% | 101.27% | 78.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 162.66% | 188.43% | 117.73% | 101.27% | 78.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 162.66% | 188.43% | 117.73% | 101.27% | 78.43% |
| EBIT | 80.48% | 80.94% | 121.07% | 95.67% | 63.86% |
| EBITDA | -- | -- | 128.04% | 105.22% | 69.53% |
| EPS Basic | 220.22% | 183.98% | 115.46% | 101.03% | 86.41% |
| Normalized Basic EPS | 84.25% | 78.95% | 106.62% | 92.57% | 80.20% |
| EPS Diluted | 220.22% | 183.98% | 115.46% | 101.03% | 86.41% |
| Normalized Diluted EPS | 84.25% | 78.95% | 106.62% | 92.57% | 80.20% |
| Average Basic Shares Outstanding | 297.38% | 3.62% | 9.14% | 27.79% | 56.73% |
| Average Diluted Shares Outstanding | 297.38% | 3.62% | 9.14% | 27.79% | 56.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |